Dosing & Uses
Geographic Atrophy
Pending FDA approval for geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Next:
Pharmacology
Mechanism of Action
Targeted complement-3 (C3) therapy designed to regulate excessive activation of the complement cascade
Geographic atrophy (GA) is an advanced form of age-related macular degeneration
GA is caused by destruction of retinal cells through irreversible lesion growth that is driven by excessive complement activation
C3 is the only target that can precisely control the complement cascade due to its central location
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
